TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1969-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.ttuhsc.edu
Study Reveals Significant Pregnancy Risks for Minority Women with Cancer
New research from Texas Tech University Health Sciences Center shows racial and ethnic minority women with cancer face up to 40% higher risk of adverse pregnancy outcomes compared to their white counterparts.
Breakthrough Medications Show Promise in Reducing Lipoprotein(a) Levels by Up to 90%
Two novel therapies - oral muvalaplin and injectable zerlasiran - demonstrate remarkable efficacy in lowering lipoprotein(a) levels by 80-90% with minimal side effects in clinical trials.
Optimizing Kidney Cancer Treatment: Keytruda, Inlyta, and Novel Approaches for Non-Clear Cell RCC
• Considerations for discontinuing Keytruda (pembrolizumab) and Inlyta (axitinib) after two years involve balancing recurrence risk and side effects, necessitating individualized patient-physician discussions. • For non-clear cell chromophobe renal cell carcinoma, IO-TKI combinations like Lenvima (lenvatinib) plus Keytruda or Cabometyx (cabozantinib) plus Opdivo (nivolumab) show promise, with treatment choice depending on approval status. • Managing fatigue and chronic kidney disease in RCC patients requires investigating reversible causes and employing supportive measures, with nephrologist involvement for significant renal impairment.